Protagonist Therapeutics, Inc

(NASDAQ:PTGX)

Latest On Protagonist Therapeutics, Inc (PTGX):

Date/Time Type Description Signal Details
2023-05-26 01:04 ESTNewsProtagonist Therapeutics Sees Steady If Bumpy ProgressN/A
2023-05-24 20:54 ESTNewsProtagonist Therapeutics: All Quiet Heading Into An Important H2 2023N/A
2023-05-12 13:28 ESTNewsProtagonist Therapeutics and Janssen's collaboration shows promise for oral therapy for IL-23-mediated diseasesN/A
2023-05-05 17:50 ESTNewsProtagonist GAAP EPS of -$0.67 in-lineN/A
2023-04-05 11:14 ESTNewsProtagonist Therapeutics prices $100M offeringN/A
2023-04-04 19:17 ESTNewsProtagonist falls on $100M public offeringN/A
2023-03-16 06:46 ESTNewsProtagonist GAAP EPS of -$0.69 misses by $0.10N/A
2023-03-09 21:16 ESTNewsProtagonist Therapeutics: More Good News Likely To ComeN/A
2023-03-07 23:28 ESTNewsJohnson & Johnson, Protagonist succeed in mid-stage trial for psoriasis candidateN/A
2023-03-07 08:43 ESTNewsCDTX, PTGX and TAST among premarket gainersN/A
2022-11-08 17:47 ESTNewsProtagonist GAAP EPS of -$0.64 beats by $0.23N/A
2022-08-05 06:50 ESTNewsProtagonist GAAP EPS of -$0.84 beats by $0.10N/A
2022-06-15 13:34 ESTNewsProtagonist Therapeutics (PTGX) Presents At Jefferies Healthcare Conference - SlideshowN/A
2022-06-08 23:40 ESTNewsProtagonist: Too Many Red FlagsN/A
2022-06-01 03:40 ESTNewsProtagonist Therapeutics (PTGX) Presents at Digestive Disease Week (DDW) 2022N/A
2022-05-05 08:14 ESTNewsProtagonist GAAP EPS of -$0.43 beats by $0.20, revenue of $25.7M beats by $8.65MN/A
2022-04-26 17:35 ESTNewsProtagonist hits 52-week low as Street reacts to data for ulcerative colitis candidateN/A
2022-04-26 01:38 ESTNewsProtagonist falls on data from phase 2 study of PN-943 to treat ulcerative colitisN/A
2022-04-15 02:54 ESTNewsProtagonist down 22% after FDA plans to rescind Breakthrough Therapy designation for rusfertideN/A
2022-03-29 08:38 ESTNewsAsif Ali is the new finance chief at Protagonist TherapeuticsN/A
2022-02-28 17:25 ESTNewsProtagonist GAAP EPS of -$0.77 beats by $0.02, revenue of $8.62M beats by $4.62MN/A
2022-02-01 13:28 ESTNewsProtagonist Is Still Being Undervalued Like There's Real RiskN/A
2021-12-10 01:25 ESTNewsProtagonist Therapeutics (PTGX) Investor Presentation - SlideshowN/A
2021-12-02 23:48 ESTNewsProtagonist chooses candidate to advance into phase 2 in collaboration with JanssenN/A
2021-11-15 11:02 ESTNewsPhase 2a data supports Protagonist genetic liver disease drug rusfertideN/A
2021-10-12 11:34 ESTNewsJ.P. Morgan upgrades Protagonist to overweight following clinical hold removalN/A
2021-10-11 16:22 ESTNewsProtagonist gains nearly double after FDA removes clinical hold on rusfertide programN/A
2021-10-11 16:21 ESTNewsProtagonist price target raised at Northland following removal of clinical holdN/A
2021-10-06 15:26 ESTNewsPTGX is at high risk of performing badlyN/A
2021-09-30 21:08 ESTNewsProtagonist Therapeutics: How To Buy The DipN/A
2021-09-28 00:11 ESTNewsWarning: PTGX has been downgraded to Very BearishN/A
2021-09-25 08:13 ESTNewsBELLUS Health, Akoya Biosciences lead weekly healthcare gainers; Protagonist trailN/A
2021-09-22 04:02 ESTNewsProtagonist loses more than half after FDA placed clinical hold on rusfertide studiesN/A
2021-09-22 04:01 ESTNewsBELLUS Health, Akoya Biosciences lead weakly healthcare gainers; Protagonist trailN/A
2021-09-22 04:00 ESTNewsProtagonist extends slide as regulatory setback prompts downgrade at JP MorganN/A
2021-09-22 03:59 ESTNewsWarning: PTGX has been downgraded to Very Bearish.N/A
2021-08-10 10:13 ESTNewsProtagonist Therapeutics resolves contract dispute with Zealand PharmaN/A
2021-07-21 20:41 ESTNewsDosing underway in Protagonist Therapeutics' early-stage study of PN-232N/A
2021-07-21 20:32 ESTNewsProtagonist wins FDA Breakthrough Therapy Designation for blood cancer therapyN/A
2021-07-21 20:24 ESTNewsProtagonist climbs on positive effect in mid-stage study for rusfertide in polycythemia veraN/A
2021-07-21 20:23 ESTNewsBiogen could reach over $600/share: Goldman Sachs, CRISPR upgraded on follow-up data; more in today’s analyst actionN/A
2021-07-21 20:22 ESTNewsProtagonist Therapeutics slumps 7.5% on raising $100M via public offeringN/A
2021-07-21 20:22 ESTNewsRAPT, SIOX, ACHL and PTGX among after-hours moversN/A
2021-07-21 20:21 ESTNewsProtagonist Therapeutics secures $115M capital via equity raiseN/A
2021-07-21 20:16 ESTNewsProtagonist Therapeutics closes $132M capital raiseN/A
2021-05-05 01:39 ESTNewsProtagonist EPS beats by $0.03, beats on revenueN/A
2021-03-12 04:31 ESTFinancialsCompany financials have been released.Neutral
2021-03-12 04:31 ESTAnalyst RatingThe Analyst Target Price has increased from $35.4 to $37.Buy
2021-03-11 12:47 ESTNewsProtagonist Therapeutics, Inc. (PTGX) CEO Dinesh Patel on Q4 2020 Results - Earnings Call TranscriptN/A
2021-03-11 04:23 ESTEarnings EstimateAn EPS average of -$1.48 is estimated for the 2022 year.Sell

About Protagonist Therapeutics, Inc (PTGX):

Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. It is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PTG-200, an oral, interleukin-23 receptor specific antagonist peptide, which is in phase II clinical trial for the treatment of moderate-to-severe Crohn's disease; and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase II clinical trial for treating inflammatory bowel disease (IBD). The company has a license and collaboration agreement with Janssen Biotech, Inc. for the development, manufacture, and commercialization of PTG-200 for the treatment of Crohn's disease and ulcerative colitis; and PN-235 and PN-232 oral interleukin-23 receptor antagonist candidates for IBD and non-IBD indications. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

PTGX Quotes by TradingView

See Advanced Chart

General

  • Name Protagonist Therapeutics, Inc
  • Symbol PTGX
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 79
  • Fiscal Year EndDecember
  • IPO Date2016-08-11
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.protagonist-inc.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 37.31
  • Price/Book (Most Recent Quarter) 4.86
  • Enterprise Value Revenue 37.04
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$1.97
  • Next Year EPS Estimate -$2.12
  • Next Quarter EPS Estimate -$0.54
  • Profit Margin -231%
  • Operating Margin -225%
  • Return on Assets -17%
  • Return on Equity -37%
  • Revenue 28.63 million
  • Earnings Per Share -$2.74
  • Revenue Per Share $0.83
  • Gross Profit 28.63 million
  • Quarterly Earnings Growth 107.8%
View More

Highlights

  • Market Capitalization 1.36 billion
  • EBITDA -70271000
  • Analyst Target Price $37
  • Book Value Per Share $6.39
View More

Share Statistics

  • Shares Outstanding 43.81 million
  • Shares Float 27.88 million
  • % Held by Insiders 161%
  • % Held by Institutions 93.65%
  • Shares Short 2.77 million
  • Shares Short Prior Month 2.78 million
  • Short Ratio 8.34
  • Short % of Float 7%
  • Short % of Shares Outstanding 6%
View More

Technicals

  • Beta 1.55
  • 52 Week High $31.58
  • 52 Week Low $5.44
  • 50 Day Moving Average 26.03
  • 200 Day Moving Average 22.63
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Protagonist Therapeutics, Inc (PTGX) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Protagonist Therapeutics, Inc (PTGX) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-10$5.65 million-$0.48-$0.48-0.61%
2020-09-302020-11-04$N/A-$0.21-$0.6165.71%
2020-06-302020-08-06$N/A-$0.59-$0.57-2.91%
2020-03-312020-05-07$3.65 million-$0.72-$0.69-4.05%
2019-12-312020-03-10$2.72 million-$0.63-$0.652.78%
2019-09-302019-11-06$4.14 million-$0.61-$0.7720.26%
2019-06-302019-08-07$-8189000-$1.18-$0.39-206.49%
2019-03-312019-05-08$1.56 million-$0.58-$0.56-4.5%
2018-12-312019-03-12$2.35 million-$0.57-$0.47-20.25%
2018-09-302018-11-06$6.12 million-$0.38-$0.37-1.79%
2018-06-302018-08-07$11.67 million-$0.41-$0.30-35.18%
2018-03-312018-05-09$10.78 million-$0.36-$0.24-50%
2017-12-312018-03-07$11.28 million-$0.15-$0.3455.88%
2017-09-302017-11-06$8.78 million-$0.29-$0.8163.98%
2017-06-302017-08-08$N/A-$0.89-$0.86-4.09%
2017-03-312017-05-10$N/A-$0.84-$0.67-26.32%
2016-12-312017-03-07$N/A-$0.67-$0.52-28.85%
2016-09-302016-11-14$N/A-$0.87-$0.64-35.94%
2016-06-302016-07-11$N/A-$40.89-$0.83-4826.51%

Protagonist Therapeutics, Inc (PTGX) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development 19.49 million N/A N/A 18.77 million 15.91 million
Income Before Tax -18.89 million N/A N/A -19.9 million -16.65 million
Selling General Administrative 4.99 million N/A N/A 4.58 million 4.11 million
Gross Profit N/A N/A N/A N/A 2.72 million
Ebit -18.76 million N/A N/A -19 million -17.3 million
Operating Income -18.83 million N/A N/A -19.7 million -17.3 million
Income Tax Expense N/A N/A 1.13 million 176000 856000
Total Revenue 5.65 million N/A N/A 3.65 million 2.72 million
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net -9000 N/A N/A -490000 654000
Net Income From Continuing Operations -18.89 million N/A N/A -20.08 million -17.5 million
Net Income Applicable to Common Shares -18.89 million -7.76 million -19.42 million -20.08 million -17.5 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A N/A N/A -32.35 million
Change to Liabilities -13.18 million -5.87 million -1.57 million N/A -4.06 million
Total Cash Flow from Investing Activities -54.12 million -5.17 million 42.73 million N/A -32.04 million
Net Borrowings N/A -10.52 million N/A N/A N/A
Total Cash Flow from Financial Activities N/A N/A N/A N/A 25.24 million
Change to Operating Activities 1.85 million -590000 -679000 N/A 725000
Change in Cash N/A N/A N/A N/A -20.95 million
Total Cash from Operating Activities -16.29 million -21.48 million -15.85 million N/A -14.25 million
Depreciation N/A N/A N/A N/A 639000
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A 2.94 million
Other Cash Flow from Financing Activities N/A -7000 -7000 N/A N/A
Change to Net Income 1.97 million 3.18 million 2.62 million N/A 1.91 million
Capital Expenditures N/A N/A N/A N/A -309000
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities 44.86 million N/A N/A 72.24 million N/A
Total Stockholder Equity 279.61 million N/A N/A 62.67 million N/A
Other Current Liabilities 15.94 million 18.84 million N/A N/A N/A
Total Assets 324.47 million N/A N/A 134.9 million N/A
Common Stock N/A N/A N/A N/A N/A
Other Current Assets 6.29 million 10000 N/A 10000 N/A
Retained Earnings -283.81 million -264.93 million -257.16 million -237.74 million N/A
Other Liabilities 121000 4.28 million 16.88 million 20.42 million N/A
Other Assets 450000 450000 450000 1.53 million N/A
Cash 117.36 million N/A N/A 60.22 million N/A
Total Current Liabilities 40.24 million 38.56 million N/A 36.37 million N/A
Other Stockholder Equity 28000 -88000 -208000 107000 N/A
Property, Plant & Equipment 1.46 million 6.69 million 7.06 million 7.38 million N/A
Total Current Assets 315.61 million 204.15 million N/A 125.99 million N/A
Long Term Investments 2 million N/A N/A N/A N/A
Net Tangible Assets 279.61 million 169.59 million 167.49 million 62.67 million N/A
Short Term Investments 188.45 million N/A N/A 57.3 million N/A
Long Term Debt N/A N/A N/A 9.83 million N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 24.31 million 2.8 million N/A 3.7 million N/A

Protagonist Therapeutics, Inc (PTGX) Chart:

Protagonist Therapeutics, Inc (PTGX) News:

Below you will find a list of latest news for Protagonist Therapeutics, Inc (PTGX) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Protagonist Therapeutics, Inc (PTGX) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-12-202.50CALL0 0392.7TRUE00
2024-12-2050CALL0 0280.66TRUE00
2024-12-207.50CALL0 0222.52TRUE00
2024-12-20100CALL0 0183.42TRUE00
2024-12-2012.518.6CALL0 30154.01TRUE00
2024-12-20158.05CALL0 20135.6TRUE00
2024-12-2017.511.8CALL0 10110.79TRUE00
2024-12-20205.6CALL0 8128.41TRUE00
2024-12-2022.513.5CALL0 1109.03TRUE00
2024-12-202513.4CALL0 4111.4TRUE00
2024-12-20308CALL0 5101.12TRUE00
2024-12-20359CALL0 1694.15TRUE00
2024-12-204010.7CALL0 3785.87TRUE00
2024-12-20456.1CALL0 2387.03FALSE00
2024-12-20504.7CALL0 1181.71FALSE00
2024-12-20550CALL0 082.74FALSE00
2024-12-20602.25CALL0 785.56FALSE00
2024-12-20651.7CALL0 420FALSE00
2024-12-20700CALL0 20FALSE00
2024-12-202.50PUT0 00FALSE00
2024-12-2050PUT0 00FALSE00
2024-12-207.50PUT0 00FALSE00
2024-12-20100PUT0 00FALSE00
2024-12-2012.50PUT0 00FALSE00
2024-12-20150.6PUT0 20FALSE00
2024-12-2017.51.05PUT0 40FALSE00
2024-12-20201.7PUT0 20FALSE00
2024-12-2022.52.1PUT0 20FALSE00
2024-12-20250PUT0 00FALSE00
2024-12-20301.25PUT0 00FALSE00
2024-12-20352.1PUT0 395.44FALSE00
2024-12-20402.35PUT0 384.82FALSE00
2024-12-20454.4PUT0 280.99TRUE00
2024-12-20500PUT0 076.06TRUE00
2024-12-20550PUT0 090.16TRUE00
2024-12-20600PUT0 079.02TRUE00
2024-12-20650PUT0 077.96TRUE00
2024-12-20700PUT0 092.08TRUE00
2025-01-17150CALL0 0124.96TRUE00
2025-01-1717.50CALL0 0123.12TRUE00
2025-01-17200CALL0 096.71TRUE00
2025-01-1722.514.9CALL0 20111.69TRUE00
2025-01-172512.8CALL0 20107.07TRUE00
2025-01-173016.7CALL0 799.38TRUE00
2025-01-173512.7CALL0 594.01TRUE00
2025-01-174011.25CALL0 191.85TRUE00
2025-01-17456.5CALL0 4284.92FALSE00
2025-01-17505.48CALL0 686.97FALSE00
2025-01-17555.1CALL0 681.84FALSE00
2025-01-17600CALL0 082.81FALSE00
2025-01-17653CALL0 1781.43FALSE00
2025-01-17702.1CALL0 80FALSE00
2025-01-17150PUT0 00FALSE00
2025-01-1717.50PUT0 00FALSE00
2025-01-17200PUT0 00FALSE00
2025-01-1722.50PUT0 00FALSE00
2025-01-17250PUT0 00FALSE00
2025-01-17301.5PUT0 50FALSE00
2025-01-17350PUT0 086.48FALSE00
2025-01-17400PUT0 097.48FALSE00
2025-01-17450PUT0 091.14TRUE00
2025-01-17500PUT0 076.26TRUE00
2025-01-17550PUT0 085.08TRUE00
2025-01-17600PUT0 087.64TRUE00
2025-01-17650PUT0 086.29TRUE00
2025-01-17700PUT0 076.99TRUE00
2025-04-1722.520.85CALL0 2091.45TRUE00
2025-04-172518.75CALL0 2096.91TRUE00
2025-04-17300CALL0 090.37TRUE00
2025-04-173515.6CALL0 393.11TRUE00
2025-04-17400CALL0 086.69TRUE00
2025-04-174510.1CALL0 1185.71FALSE00
2025-04-17508.21CALL0 2179.97FALSE00
2025-04-17557.6CALL0 1475.67FALSE00
2025-04-17600CALL0 079.05FALSE00
2025-04-17650CALL0 080.11FALSE00
2025-04-17700CALL0 778.34FALSE00
2025-04-1722.52.4PUT0 10FALSE00
2025-04-17252.9PUT0 20FALSE00
2025-04-17304PUT0 183.53FALSE00
2025-04-17354.7PUT2 59778FALSE4.70
2025-04-17407.4PUT0 30084.31FALSE00
2025-04-17459.8PUT4 4477.34TRUE0.10.01
2025-04-175012.9PUT0 182.94TRUE00
2025-04-17550PUT0 079.09TRUE00
2025-04-176019.4PUT0 278.63TRUE00
2025-04-17650PUT0 077.11TRUE00
2025-04-17700PUT0 081.74TRUE00
2025-07-1822.50CALL0 085.36TRUE00
2025-07-18250CALL0 084.19TRUE00
2025-07-183016.5CALL0 082.73TRUE00
2025-07-18350CALL0 079.07TRUE00
2025-07-18400CALL0 077.91TRUE00
2025-07-184512.9CALL0 578.71FALSE00
2025-07-18500CALL0 075.26FALSE00
2025-07-18550CALL0 068.5FALSE00
2025-07-18605CALL0 2372.08FALSE00
2025-07-18656.7CALL0 270.93FALSE00
2025-07-18700CALL0 071.99FALSE00
2025-07-1822.50PUT0 00FALSE00
2025-07-18250PUT0 00FALSE00
2025-07-18300PUT0 074.63FALSE00
2025-07-18356.3PUT0 1581.78FALSE00
2025-07-18400PUT0 075.78FALSE00
2025-07-18450PUT0 069.44TRUE00
2025-07-185012.6PUT0 1072.56TRUE00
2025-07-18550PUT0 070.53TRUE00
2025-07-186021PUT2 071.08TRUE210
2025-07-18650PUT0 071.62TRUE00
2025-07-18700PUT0 067.33TRUE00

Latest PTGX Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST13$7.08
Jun 13, 2022 7:59 PM EST8$7.07
Jun 13, 2022 7:59 PM EST1$7.07
Jun 13, 2022 7:59 PM EST14$7.07
Jun 13, 2022 7:59 PM EST34$7.09

Protagonist Therapeutics, Inc (PTGX) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000083423720009556/0000834237-20-009556-index.htm
2018-09-18UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1377121/000000000018029279/0000000000-18-029279-index.htm
2019-11-21UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1377121/000000000019015720/0000000000-19-015720-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000031506619001298/0000315066-19-001298-index.htm
2020-02-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000031506620001141/0000315066-20-001141-index.htm
2020-02-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000083423720008027/0000834237-20-008027-index.htm
2020-06-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000083423720009556/0000834237-20-009556-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000090266419000928/0000902664-19-000928-index.htm
2020-05-22SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000090266420002197/0000902664-20-002197-index.htm
2018-08-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000092189518002281/0000921895-18-002281-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000092189519000465/0000921895-19-000465-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000092189520000521/0000921895-20-000521-index.htm
2018-07-02SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000093041318002140/0000930413-18-002140-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000093041319000575/0000930413-19-000575-index.htm
2018-08-07424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1377121/000104746918005447/0001047469-18-005447-index.htm
2018-09-07S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1377121/000104746918006015/0001047469-18-006015-index.htm
2018-09-26424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1377121/000104746918006444/0001047469-18-006444-index.htm
2019-04-26DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1377121/000104746919002642/0001047469-19-002642-index.htm
2019-10-31S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1377121/000104746919006014/0001047469-19-006014-index.htm
2019-11-27424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1377121/000104746919006551/0001047469-19-006551-index.htm
2020-04-16DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1377121/000104746920002368/0001047469-20-002368-index.htm
2020-05-11424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1377121/000104746920002943/0001047469-20-002943-index.htm
2020-05-13424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1377121/000104746920003025/0001047469-20-003025-index.htm
2018-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465918049635/0001104659-18-049635-index.htm
2018-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465918049963/0001104659-18-049963-index.htm
2018-09-20CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1377121/000110465918057889/0001104659-18-057889-index.htm
2018-10-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465918063178/0001104659-18-063178-index.htm
2018-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465918066340/0001104659-18-066340-index.htm
2018-11-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465918070107/0001104659-18-070107-index.htm
2018-12-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465918075322/0001104659-18-075322-index.htm
2019-03-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919014250/0001104659-19-014250-index.htm
2019-03-12S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1377121/000110465919014317/0001104659-19-014317-index.htm
2019-03-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919017130/0001104659-19-017130-index.htm
2019-04-26DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1377121/000110465919024116/0001104659-19-024116-index.htm
2019-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919027659/0001104659-19-027659-index.htm
2019-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919027662/0001104659-19-027662-index.htm
2019-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919029003/0001104659-19-029003-index.htm
2019-05-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919032445/0001104659-19-032445-index.htm
2019-06-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919035338/0001104659-19-035338-index.htm
2019-06-17SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000110465919035942/0001104659-19-035942-index.htm
2019-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919044426/0001104659-19-044426-index.htm
2019-10-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919058437/0001104659-19-058437-index.htm
2019-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919060537/0001104659-19-060537-index.htm
2019-11-20CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1377121/000110465919065981/0001104659-19-065981-index.htm
2019-11-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919068332/0001104659-19-068332-index.htm
2019-12-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919069217/0001104659-19-069217-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000110465920021728/0001104659-20-021728-index.htm
2020-02-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920024253/0001104659-20-024253-index.htm
2020-03-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920031381/0001104659-20-031381-index.htm
2020-03-10S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1377121/000110465920031453/0001104659-20-031453-index.htm
2020-03-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920035420/0001104659-20-035420-index.htm
2020-04-16DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1377121/000110465920047714/0001104659-20-047714-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920058140/0001104659-20-058140-index.htm
2020-05-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920059922/0001104659-20-059922-index.htm
2020-05-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920067747/0001104659-20-067747-index.htm
2020-06-08SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1377121/000110465920070830/0001104659-20-070830-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920091424/0001104659-20-091424-index.htm
2020-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920094719/0001104659-20-094719-index.htm
2020-09-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920104437/0001104659-20-104437-index.htm
2020-10-028-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920111763/0001104659-20-111763-index.htm
2020-11-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920121408/0001104659-20-121408-index.htm
2018-12-10SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000119312518345594/0001193125-18-345594-index.htm
2019-01-24SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000119312519015661/0001193125-19-015661-index.htm
2019-02-05SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000119312519028285/0001193125-19-028285-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000119312519040996/0001193125-19-040996-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000119312520038117/0001193125-20-038117-index.htm
2018-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919118037316/0001209191-18-037316-index.htm
2018-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919118037317/0001209191-18-037317-index.htm
2018-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919118037318/0001209191-18-037318-index.htm
2018-07-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919118042575/0001209191-18-042575-index.htm
2018-08-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919118047543/0001209191-18-047543-index.htm
2018-08-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919118047547/0001209191-18-047547-index.htm
2018-08-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919118047548/0001209191-18-047548-index.htm
2018-08-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919118047549/0001209191-18-047549-index.htm
2019-01-093Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119003141/0001209191-19-003141-index.htm
2019-01-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119003606/0001209191-19-003606-index.htm
2019-01-143Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119003645/0001209191-19-003645-index.htm
2019-01-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119003994/0001209191-19-003994-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119008675/0001209191-19-008675-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119008679/0001209191-19-008679-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119008690/0001209191-19-008690-index.htm
2019-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119015926/0001209191-19-015926-index.htm
2019-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119015927/0001209191-19-015927-index.htm
2019-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119015930/0001209191-19-015930-index.htm
2019-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119015935/0001209191-19-015935-index.htm
2019-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119015939/0001209191-19-015939-index.htm
2019-04-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119022776/0001209191-19-022776-index.htm
2019-04-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119022784/0001209191-19-022784-index.htm
2019-05-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119030616/0001209191-19-030616-index.htm
2019-06-033Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119034081/0001209191-19-034081-index.htm
2019-06-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119034082/0001209191-19-034082-index.htm
2019-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119036195/0001209191-19-036195-index.htm
2019-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119036203/0001209191-19-036203-index.htm
2019-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119036204/0001209191-19-036204-index.htm
2019-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119036207/0001209191-19-036207-index.htm
2019-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119036211/0001209191-19-036211-index.htm
2019-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119036214/0001209191-19-036214-index.htm
2019-08-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119045195/0001209191-19-045195-index.htm
2019-08-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119045196/0001209191-19-045196-index.htm
2019-11-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119058295/0001209191-19-058295-index.htm
2019-12-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119058799/0001209191-19-058799-index.htm
2019-12-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119058800/0001209191-19-058800-index.htm
2019-12-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119058839/0001209191-19-058839-index.htm
2019-12-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119058853/0001209191-19-058853-index.htm
2020-02-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120014088/0001209191-20-014088-index.htm
2020-02-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120014090/0001209191-20-014090-index.htm
2020-02-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120014092/0001209191-20-014092-index.htm
2020-02-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120014097/0001209191-20-014097-index.htm
2020-02-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120014100/0001209191-20-014100-index.htm
2020-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120018645/0001209191-20-018645-index.htm
2020-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120018752/0001209191-20-018752-index.htm
2020-03-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120020714/0001209191-20-020714-index.htm
2020-04-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120023949/0001209191-20-023949-index.htm
2020-05-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120026593/0001209191-20-026593-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120033016/0001209191-20-033016-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120033020/0001209191-20-033020-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120033022/0001209191-20-033022-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120033026/0001209191-20-033026-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120033031/0001209191-20-033031-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120033032/0001209191-20-033032-index.htm
2020-08-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120046427/0001209191-20-046427-index.htm
2020-08-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120047233/0001209191-20-047233-index.htm
2020-08-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120047246/0001209191-20-047246-index.htm
2018-08-20SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000121465918005609/0001214659-18-005609-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000121465919001113/0001214659-19-001113-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000121465920001392/0001214659-20-001392-index.htm
2019-07-01SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000131924419000056/0001319244-19-000056-index.htm
2019-12-16SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000149315219019237/0001493152-19-019237-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000149315220002364/0001493152-20-002364-index.htm
2018-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000155837018006590/0001558370-18-006590-index.htm
2018-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1377121/000155837018006639/0001558370-18-006639-index.htm
2018-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1377121/000155837018008657/0001558370-18-008657-index.htm
2019-03-1210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1377121/000155837019001853/0001558370-19-001853-index.htm
2019-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1377121/000155837019004481/0001558370-19-004481-index.htm
2019-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1377121/000155837019007515/0001558370-19-007515-index.htm
2019-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1377121/000155837019010201/0001558370-19-010201-index.htm
2020-03-1010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1377121/000155837020002334/0001558370-20-002334-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1377121/000155837020005785/0001558370-20-005785-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1377121/000155837020009681/0001558370-20-009681-index.htm
2020-11-0410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1377121/000155837020012597/0001558370-20-012597-index.htm
2018-09-21EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1377121/999999999518002437/9999999995-18-002437-index.htm
2019-11-22EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1377121/999999999519002648/9999999995-19-002648-index.htm

Protagonist Therapeutics, Inc (PTGX) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Protagonist Therapeutics, Inc (PTGX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 161%
Institutional Ownership: 9365%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-08-11CHAITAN PHD KHOSLADirectorSell2,499.0017.1942,952.060.00https://www.sec.gov/Archives/edgar/data/1377121/000120919120046427/0001209191-20-046427-index.htm
2019-12-03Donald A. KalkofenChief Financial OfficerBuy562.005.092,860.581,175.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119058800/0001209191-19-058800-index.htm
2020-03-12HAROLD E SELICKDirectorBuy12,000.006.7080,400.0015,310.00https://www.sec.gov/Archives/edgar/data/1377121/000120919120018645/0001209191-20-018645-index.htm
2019-02-28Suneel GuptaEVP Clinical OperationsBuy7,500.0017,500.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119015926/0001209191-19-015926-index.htm
2019-02-06Richard S. ShamesChief Medical OfficerSell2,580.007.7119,891.8024,178.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119008675/0001209191-19-008675-index.htm
2020-08-11CHAITAN PHD KHOSLADirectorBuy2,499.001.894,723.112,499.00https://www.sec.gov/Archives/edgar/data/1377121/000120919120046427/0001209191-20-046427-index.htm
2019-02-28Samuel R SaksChief Development OfficerBuy2,500.002,500.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119015930/0001209191-19-015930-index.htm
2019-02-06Richard S. ShamesChief Medical OfficerSell198.008.151,613.7026,758.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119008675/0001209191-19-008675-index.htm
2018-08-15Richard S. ShamesChief Medical OfficerBuy18,750.0026,956.00https://www.sec.gov/Archives/edgar/data/1377121/000120919118047548/0001209191-18-047548-index.htm
2018-08-15Thomas P. O'NeilChief Financial OfficerBuy21,100.0030,560.00https://www.sec.gov/Archives/edgar/data/1377121/000120919118047549/0001209191-18-047549-index.htm
2019-03-01Richard S. ShamesChief Medical OfficerSell657.008.035,275.7132,021.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119015927/0001209191-19-015927-index.htm
2019-02-28Richard S. ShamesChief Medical OfficerBuy8,500.0032,678.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119015927/0001209191-19-015927-index.htm
2019-04-01HAROLD E SELICKDirectorBuy3,310.001.314,336.103,310.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119022784/0001209191-19-022784-index.htm
2018-08-15DINESH V PH D PATELPresident and CEOBuy82,050.00345,829.00https://www.sec.gov/Archives/edgar/data/1377121/000120919118047547/0001209191-18-047547-index.htm
2019-02-06DINESH V PH D PATELPresident and CEOSell10,132.007.7178,117.72357,264.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119008690/0001209191-19-008690-index.htm
2019-02-06DINESH V PH D PATELPresident and CEOSell777.008.106,292.22367,396.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119008690/0001209191-19-008690-index.htm
2019-01-11DINESH V PH D PATELPresident and CEOBuy22,344.001.1625,919.04368,173.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119003606/0001209191-19-003606-index.htm
2019-02-06David Y LiuChief Scientific OfficerSell3,821.007.7429,561.5537,007.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119008679/0001209191-19-008679-index.htm
2019-08-06DINESH V PH D PATELPresident and CEOSell10,792.008.8595,535.10374,792.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119045195/0001209191-19-045195-index.htm
2019-11-26DINESH V PH D PATELPresident and CEOBuy4,000.001.164,640.00379,824.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119058295/0001209191-19-058295-index.htm
2019-03-01DINESH V PH D PATELPresident and CEOSell2,183.008.0317,529.49383,831.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119015935/0001209191-19-015935-index.htm
2019-02-28DINESH V PH D PATELPresident and CEOBuy28,750.00386,014.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119015935/0001209191-19-015935-index.htm
2019-12-03DINESH V PH D PATELPresident and CEOBuy10,000.005.5555,500.00389,824.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119058799/0001209191-19-058799-index.htm
2018-08-15David Y LiuChief Scientific OfficerBuy25,800.0040,828.00https://www.sec.gov/Archives/edgar/data/1377121/000120919118047543/0001209191-18-047543-index.htm
2019-12-03DINESH V PH D PATELPresident and CEOBuy20,000.005.65113,000.00409,824.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119058799/0001209191-19-058799-index.htm
2020-03-12DINESH V PH D PATELPresident and CEOBuy18,344.001.1621,279.04429,990.00https://www.sec.gov/Archives/edgar/data/1377121/000120919120018752/0001209191-20-018752-index.htm
2020-03-20DINESH V PH D PATELPresident and CEOBuy10,000.001.8918,900.00439,990.00https://www.sec.gov/Archives/edgar/data/1377121/000120919120020714/0001209191-20-020714-index.htm
2019-12-03Suneel GuptaEVP Clinical OperationsBuy30,000.005.13153,900.0049,500.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119058839/0001209191-19-058839-index.htm
2019-08-06David Y LiuChief Scientific OfficerSell3,395.008.8530,044.0549,802.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119045196/0001209191-19-045196-index.htm
2019-03-01David Y LiuChief Scientific OfficerSell810.008.036,504.3051,197.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119015939/0001209191-19-015939-index.htm
2019-02-28David Y LiuChief Scientific OfficerBuy15,000.0052,007.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119015939/0001209191-19-015939-index.htm
2019-12-03Donald A. KalkofenChief Financial OfficerBuy613.005.103,126.30613.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119058800/0001209191-19-058800-index.htm
2019-12-03Bryan GiraudoDirectorBuy8,000.005.7045,620.008,000.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119058853/0001209191-19-058853-index.htm